These findings support the notion that ATR, CHK1 and WEE1 inhibitors would sensitise tumours that are intrinsically resistant to PARPi, by virtue of HRP genotype or acquire resistance through restoration of HRR function clinically. This evidence concerns the gene WEE1 and neoplasm.